/
LBRX
$32.64+$0.72 (+2.26%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$915.4M
29M shares
52-week range
$13.36 – $33.47
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.44%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$15.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — |
| R&D | $1.3M | $7.8M | $51.2M | $16.7M |
| Operating income | −$2.8M | −$11.4M | −$64.8M | −$30.4M |
| EBITDA | −$12.2M | −$1.4M | −$63.0M | −$24.9M |
| Net income | −$14.3M | −$6.3M | −$63.1M | −$25.2M |
| Net margin | — | — | — | — |
| EPS (diluted) | -4.05 | -1.77 | -17.83 | -1.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-3.52 | $-3.66–$-3.23 | 5 |
| 2027 | $0 | $-4.39 | $-5.06–$-3.64 | 5 |
| 2028 | $0 | $-4.12 | $-5.11–$-3.04 | 3 |
| 2029 | $56M | $-5.02 | $-5.02–$-5.02 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$9.67
Price
$32.64
Implied downside
-70%
Peer comparison
LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
www.lbpharma.us- Employees
- 27
- IPO / List date
- Sep 11, 2025
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds LBRX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in LBRX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LBRX yet.